Precipio, Inc.
PRPORESTATEMENT RISKFILING INTENSITYPrecipio, Inc. reads as Restatement Risk (composite 72/100); pressure / disclosure signals dominate the posture this cycle · primary market Life Sciences.
Lens
Disclosed M&A capital (2023–2025)
N/A
vs N/A in 2020–2022
Disclosed transactions
N/A
0/3 active fiscal years in window
Buyer archetype
Selective Buyer
Acquisition use is visible but targeted.
Composite score
72
Restatement Risk dominates · Filing Intensity
Behavioral posture, nine reads.
Each index scores the issuer 0–100 against an EDGAR-anchored definition. Scores ≥ threshold elevate the issuer into the index's constituent set; the dominant index drives the masthead label.
Active Acquirer
Companies actively deploying disclosed capital into M&A
- $9M disclosed buyer spend
Buyer Cadence
Buyer-side companies with recent filing activity
- Filed within 34d
- 332 8-Ks
Target Probability
Issuers showing target-side patterns from filings
- 49 activism filings
Spin/Carve
Issuers showing spin-off, carve-out, or sum-of-parts posture
- 49 activism filings
Pressure Watch
Issuers facing activism, governance, or control pressure
- 49 activism filings
- Latest activism 7.7y ago; heavily discounted
Distress Watch
Issuers showing financial-distress filing patterns
- 10-Q 207d stale
- 49 activism filings
Restatement Risk
DominantIssuers with accounting-integrity flags from filings
- 1 non-reliance 8-K
- 6 auditor changes
- 16 NT late filings
- Latest event 1.2y ago
Capital Velocity
Issuers with the highest filing-activity intensity
- 332 8-Ks
- 5 form types
Quiet Power
Large issuers with low signal volume and clean disclosure cadence
- Enterprise value $51M
- 10-Q 207d ago
- 3 active signals
Capital cadence.
No disclosed M&A capital in the 10-year window.
This issuer has not disclosed material acquisition spend or count in the last ten fiscal years.
Strategy posture.
The buyer's playbook in terms of strategic archetype: what each disclosed move says about how they're deploying capital.
Archetype mix
- Bolt On33%
- Technology Acquisition33%
- Geographic Expansion33%
Strategy keywords
Terms recurring across recent 10-K acquisition disclosures.
- technology_acquisition
- geographic_expansion
- bolt_on
- platform
- horizontal_consolidation
Filing language.
Direct excerpts from acquisition disclosures and strategy sections: the verbs the buyer chose, in the filings they signed.
“We are advancing personalized medicine in cardiology, oncology, and inherited diseases through our proprietary molecular technologies and world-class clinical research services.”
“We anticipate growth in all three of our business units as we commercialize new technologies and tests we have developed internally, in-licensed, or acquired.”
“We work to broaden the range of products and services we deliver to customers in target markets through acquisitions, investments and alliances.”
“We expect to seek to acquire businesses, technologies or products that will complement or expand our existing business.”
“we commercialize new technologies and tests we have developed internally, in-licensed, or acquired”
Market context.
Where this issuer sits inside its SE-Cluster rollup wedge, with disclosed-spend rank plus trading comparables against the public peer set.
Primary market
Life Sciences
- Market spend (2023–2025)
- $68.3B
- Market spend (2020–2022)
- $107.5B
- Recent vs prior
- −36%
- Issuer rank in market
- N/A
- Share of market capital
- 0.0%
Valuation positioning
PRPO trades at a +18.7-turn premium to the Life Sciences peer median of 16.1×.
- EV / Revenue
- 2.1×
- Net debt / EBITDA
- -1.8×
- Peer median EV / EBITDA
- 16.1×
Trading comparables
FMP market data · 2026-05-10
| Company | EV / EBITDA | EV / Rev | Net debt / EBITDA | Revenue | M&A 2023–2025 |
|---|---|---|---|---|---|
Precipio, Inc.PRPO | 34.7× | 2.1× | -1.8× | $24M | N/A |
| 19.1× | 4.7× | -0.0× | $45.2B | $10.8B | |
| 18.8× | 4.3× | -0.3× | $20.6B | $8B | |
| 13.3× | 3.5× | -0.1× | $35.5B | $2.2B | |
| 13.1× | 1.9× | -0.2× | $14.1B | $2.1B |
Trading multiples from FMP market data; disclosed M&A spend from the SE-Cluster EDGAR 10-K corpus. Peer set = top disclosed buyers in Life Sciences. Bars scaled to the highest EV/EBITDA in the set.
Buyer landscape.
Public buyers whose stated archetypes, target categories, and recent cadence align with this issuer as a plausible acquisition target. Scores cross EDGAR signal and disclosure overlap.
Likely buyers
No public buyers surface as a strong target-side fit on current signal.
Likely sellers / divestiture partners
No reciprocal divestiture / strategic-alternatives matches identified.
Filing activity & signal stream.
Filing cadence and event-driven signals visible on EDGAR. The signal stream below is curated from restatement / spin-carve / activism categories, providing context for any near-term call.
Filing cadence
- 10-K (annual)332026-03-30
- 10-Q (quarterly)822025-11-14
- 8-K (event)3322026-05-06
- Proxy / DEF 14A552026-04-28
- Activism (13D / DFAN / PREC)492018-09-14
Signals on file
- critical
Non-reliance disclosure
2005-05-271 Item 4.02 filing on file; financial-statement non-reliance.
- elevated
Auditor change
2025-04-106 Item 4.01 filings on file; certifying accountant change.
- watch
Late-filing notice
2019-05-1516 NT 10-K/10-Q filings on file.
- elevated
Activism on file
2018-09-1449 activist filings on file (13D, DFAN14A, PREC14A series).
- info
Signal
Serial acquisition history
- info
Signal
10-K strategy themes
- info
Signal
Restatement risk
Audited corpus.
No audited record on file for this CIK in the current v6 corpus.
This issuer has not been extracted into the v6 audited acquirer corpus yet. The brief above pulls from ranking-level aggregates and issuer-index signal only.